Chester County News and Community Website
KING OF PRUSSIA, PA — SK Life Science Labs, a subsidiary of SK Biopharmaceuticals Co., Ltd., has announced a major advancement in oncology with the discovery of PVTX-405, a potent …
SK Life Science Labs Unveils Breakthrough in Cancer Therapy with PVTX-405 Read More
WILMINGTON, DE — High-level results from the DESTINY-Breast09 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), in combination with pertuzumab, significantly improves progression-free survival (PFS) compared to the current 1st-line …
ENHERTU Combination Shows Promising Results in HER2-Positive Metastatic Breast Cancer Trial Read More
WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) showcased significant advancements in its oncology research at the American Association for Cancer Research (AACR) Annual Meeting, unveiling preclinical findings for its …
Prelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer Therapies Read More
PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) announced that its management team will host a live fireside chat on Tuesday, April 22, 2025, at 10:00 a.m. EDT to discuss …
Century Therapeutics Hosts Live Fireside Chat on Groundbreaking Cell Therapy Advances Read More WILMINGTON, DE — AstraZeneca‘s IMFINZI® (durvalumab) has gained FDA approval for use in adult patients with muscle-invasive bladder cancer (MIBC), making it the first perioperative immunotherapy available in the U.S. …
FDA Approves AstraZeneca’s IMFINZI® for Muscle-Invasive Bladder Cancer Read More
CHEYNEY, PA — Navrogen, Inc. has announced groundbreaking advancements in monoclonal antibody (mAb) and antibody-drug conjugate (ADC) development to target cancers that overexpress the humoral immunosuppressive oncology (HIO) factor ICAM-1. The …
Navrogen Advances Antibody Technology to Combat Cancer with New Findings Read More
WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader, NKT3964, by completing the dosing of the first patient cohort in a …
NiKang Advances CDK2 Degrader with Key Milestone in Cancer Treatment Trial Read More
SPRING HOUSE, PA — Third Arc Bio Inc. has administered the first dose of ARC101 to a patient in its inaugural first-in-human clinical trial. This milestone marks the company’s transition to …
Third Arc Bio Enters Clinical Stage with First Patient Dosed in ARC101 Study Read More
PHILADELPHIA, PA— Researchers at The Wistar Institute, led by Jessie Villanueva, Ph.D., have made significant strides in combating treatment-resistant melanoma. Their latest discovery focuses on inhibiting the gene S6K2, a breakthrough …
Wistar Institute Uncovers New Strategy for Treating Resistant Melanoma Read More
SAN DIEGO, CA and PHILADELPHIA, PA — BioAtla, Inc. and Context Therapeutics Inc. have entered into a significant agreement, granting Context an exclusive, worldwide license to develop and commercialize BioAtla’s BA3362, …
BioAtla and Context Therapeutics Forge Strategic Agreement for Cancer Treatment Development Read More